"Dana-Farber Cancer Institute - Merrimack Valley provides the latest hematology and medical oncology care to patients in the Merrimack Valley. The center makes it possible to offer the expertise and experience of Dana-Farber, New England’s leading cancer center, while enabling patients to enjoy the comfort and convenience of staying close to home. Expert hematologist/oncologists, supported by Dana-Farber’s vast clinical resources, offer patients the latest and most advanced treatments for cancer and blood disorders, including access to Dana-Farber’s innovative clinical trials. In addition, a range of clinical and support services is available to patients and their families, reflecting Dana-Farber’s commitment to treating the “whole patient."

During the past decade, Dana Farber-Merrimack Valley conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dana Farber-Merrimack Valley" #1 collaborator was "Cancer and Leukemia Group B" with 2 trials as a collaborator, "NCIC Clinical Trials Group" with 2 trials as a collaborator, "National Cancer Institute (NCI)" with 2 trials as a collaborator, "North Central Cancer Treatment Group" with 2 trials as a collaborator and "SWOG Cancer Research Network" with 2 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Dana Farber-Merrimack Valley" are "Stage IB Lung Non-Small Cell Carcinoma AJCC v7" (2 trials), "Stage IIA Lung Non-Small Cell Carcinoma AJCC v7" (2 trials), "Stage IIB Lung Non-Small Cell Carcinoma AJCC v7" (2 trials), "Stage IIIA Lung Non-Small Cell Cancer AJCC v7" (2 trials) and "ALK Gene Rearrangement" (1 trials). Many other conditions were trialed in "Dana Farber-Merrimack Valley" in a lesser frequency.

Most popular intervention types in "Dana Farber-Merrimack Valley" are "Drug" (9 trials), "Other" (8 trials), "Biological" (4 trials), "Behavioral" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (5 trials), "Cisplatin" (3 trials), "Gemcitabine Hydrochloride" (3 trials), "Paclitaxel" (3 trials) and "Pemetrexed Disodium" (3 trials). Other intervention names were less common.

The vast majority of trials in "Dana Farber-Merrimack Valley" are 10 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Dana Farber-Merrimack Valley". undefined are not yet recruiting, 7 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Dana Farber-Merrimack Valley, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Dana Farber-Merrimack Valley, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".